JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Ganglioside as a Therapy Target in Various Types of Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Ganglioside as a Therapy Target in Various Types of Cancer
Qamsari, Elmira Safaie; Nourazarian, Alireza; Bagheri, Salman; Motallebnezhad, Morteza;
  PDF(new window)
 Abstract
Since their discovery in 1940, it has been well established that gangliosides are associated with a number of biological pathways and cellular processes such as growth, differentiation and toxin uptake. Gangliosides are glycosphingolipids containing neuraminic acid which are expressed on the plasma membrane of cells particularly in the nervous system. Heterogeneity and structural variation in the carbohydrate chains of gangliosides contributes to unique features of each of these molecules. Thirty five years ago it was discovered that aberrant glycosylation occurs in a variety of human cancers, including aberrant glycosylation of gangliosides. Ganglioside expression in terms of quality and quantity varies in different cancers and different roles may be played. Gangliosides, by affecting the immune system, including esxpression of cytokines and adhesion molecules, may inhibit anti-tumor mechanisms, as well as having direct impact on angiogenesis, cell movement and metastasis. It should be noted that different kinds of gangliosides do not all act by the same mechanisms.
 Keywords
Gangliosides;cancer;immune system;biological pathways;
 Language
English
 Cited by
 References
1.
Battula VL, Shi Y, Evans KW, et al (2012). Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest, 122, 2066-78. crossref(new window)

2.
Bharti AC, Singh SM (2001). Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int. Immunopharmacol, 1, 155-165. crossref(new window)

3.
Birkle S, Zeng G, Gao L, Yu RK, Aubry J (2003). Role of tumorassociated gangliosides in cancer progression. Biochimie, 85, 455-63. crossref(new window)

4.
Biswas K, Richmond A, Rayman P, et al (2006). GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res, 66, 6816-25. crossref(new window)

5.
Boligan KF, Mesa C, Fernandez LE, von Gunten S (2015). Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci, 72, 1231-48. crossref(new window)

6.
Bull C, den Brok MH, Adema GJ (2014). Sweet escape: sialic acids in tumor immune evasion. Biochim Biophys Acta, 1846, 238-46.

7.
Caldwel S, Heitger A, Shen W, et al (2003) Mechanisms of ganglioside inhibition of APC function. J Immunol, 171, 1676-83. crossref(new window)

8.
Cui XB, Peng H, Li S, et al (2014). Prognostic value of PLCE1 expression in upper gastrointestinal cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 9661-6. crossref(new window)

9.
Doronin II, Vishnyakova PA, Ponomarev ED, et al (2014). Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer, 14, 295. crossref(new window)

10.
Dyatlovitskaya EV, Kandyba AG (2006). Sphingolipids in tumor metastases and angiogenesis. Biochemistry (Moscow), 71, 347-53. crossref(new window)

11.
Elgert KD, Alleva DG, Mullins DW (1998). Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol, 64, 275-90. crossref(new window)

12.
Fernandez LE, Gabri MR, Guthmann MD, et al (2010). NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol, 8 ,1-8.

13.
Fukumoto S, Mutoh T, Hasegawa T (2000). GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J Biol Chem. 275, 5832-8. crossref(new window)

14.
Garcia-Ruiz C, Morales A, Fernandez-Checa JC (2015). Glycosphingolipids and cell death: one aim, many ways. Apoptosis, 20, 607-20. crossref(new window)

15.
Gately S (2000). The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev, 19, 19-27. crossref(new window)

16.
Gu Y, Zhang J, Mi W (2008). Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells. Breast Cancer Res, 10, 1.

17.
Hakomori S (2002). Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 99, 10231-3. crossref(new window)

18.
Hata K, Tochigi T, Sato I, et al (2015). Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum. Cancer Sci, 106, 383-9. crossref(new window)

19.
Holst S, Stavenhagen K, Balog CI, et al (2013) . Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrixassisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS). Mol Cell Proteomics, 12, 3081-93. crossref(new window)

20.
Horwacik I, Rokita H (2015). Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis, 20, 679-88. crossref(new window)

21.
Kakugawa Y, Wada T, Yamaguchi K, et al (2002). Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Natl Acad Sci U S A, 99, 10718-23. crossref(new window)

22.
Krengel U, Bousquet PA (2014). Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol, 21, 325.

23.
Kwak DH, Seo BB, Chang KT, Choo YK (2011). Roles of gangliosides in mouse embryogenesis and embryonic stem cell differentiation. Exp Mol Med, 43, 379-388. crossref(new window)

24.
Labrada M, Clavell M, Bebelagua Y (2010). Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther, 10, 153-62. crossref(new window)

25.
Li Y, Huang X, Zhong W, Zhang J, Ma K (2013). Ganglioside GM3 promotes HGF-stimulatedmotility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling, Mol Cell Biochem, 382, 83-92. crossref(new window)

26.
Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S (2014). Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis, 17, 563-71. crossref(new window)

27.
Mehrabani D, Shamsdin SA, Dehghan A, Safarpour A (2014). Clinical significance of serum vascular endothelial growth factor and complement 3a levels in patients with colorectal cancer in southern Iran. Asian Pac J Cancer Prev, 15, 9713-7. crossref(new window)

28.
Miyagi T, Takahashi K, Shiozaki K, Yamaguchi K, Hosono M (2015). Plasma membrane-associated sialidase confers cancer initiation, promotion and progression. Adv Exp Med Biol, 842, 139-45. crossref(new window)

29.
Mousavi SM,Ramazani R,Gouya MM, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol. 20, 556-563.

30.
Niethammer D, Handgretinger R (1995). Clinical strategies for the treatment of neuroblastoma. Eur J Cancer. 31, 568-71. crossref(new window)

31.
Nourazarian AR, Kangari P Salmaninejad A (2014). Roles of oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev, 15, 4745-51. crossref(new window)

32.
Reis CA, Osorio H, Silva L, Gomes C, David L (2010). Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, 63, 322-9. crossref(new window)

33.
Shurin GV, Shurin MR, Bykovskaia S, et al (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res, 61, 363-9.

34.
Steelant WF, Kawakami Y, Ito A, et al (2002). Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties. FEBS letters, 531, 93-8. crossref(new window)

35.
Steiner T, Junker U, Henzgen B, et al (2001). Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur Urol, 39, 478-83. crossref(new window)

36.
Tringali C, Silvestri I, Testa F, et al (2014). Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer, 14, 560. crossref(new window)

37.
Wang Y, Cui Y, Cao F, et al (2015). Ganglioside GD1a suppresses LPS-induced pro-inflammatory cytokines in RAW264.7 macrophages by reducing MAPKs and NF-${\kappa}B$ signaling pathways through TLR4. Int Immunopharmacol, 28, 136-45. crossref(new window)

38.
Wang Z, Ma L, Zhang XM, Zhou ZX (2014). Risk of lymph node metastases from early gastric cancer in relation to depth of invasion: experience in a single institution. Asian Pac J Cancer Prev, 15, 5371-5. crossref(new window)

39.
Zamfir AD, Serb A, Vukeli Z, et al (2011). Assessment of the molecular expression and structure of gangliosides in brain metastasis of lung adenocarcinoma by an advanced approach based on fully automated chip-nanoelectrospray mass spectrometry. J Am Soc Mass Spectrom, 22, 2145-59. crossref(new window)

40.
Zeng G, Gao L, Birkle S, Yu RK (2000). Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production, Cancer Res, 60, 6670-7.